Ness Ziona, Israel, October 13th, 2009- NasVax Ltd. (TASE: NSVX), an Israeli company developing new and improved vaccines and immunotherapeutics, reports positive preclinical results for a swine influenza H1N1 vaccine formulated with its unique VaxiSomeTM liposome-based adjuvant.
The efficacy of different dosage levels of (H1N1)v A/California/7/2009 antigen administered intramuscularly to mice was compared to corresponding dosage levels of the antigen formulated with two different levels of VaxiSome. Efficacy was evaluated by assaying the level of serum antibody (HI = Hemagglutinin Inhibiting) response post dose-one and post dose-two, where HI antibodies are considered a surrogate for efficacy of influenza vaccines.
The results showed significantly increased levels of HI antibodies in mice immunized with swine flu antigen adjuvanted with VaxiSome compared to corresponding groups of unadjuvanted antigen, following one or two doses. These data support further development of VaxiSome-adjuvanted vaccine.
About NasVax
NasVax (TASE: NSVX) develops improved vaccines and immunotherapeutic products. Besides the VaxiSomeTM technology, which is an adjuvant system for enhancing the immunogenicity of vaccines and immunotherapeutics, the company has two distinct product areas.
Protea, a fully-owned subsidiary of NasVax, is developing a group-common protein-based vaccine that is a promising third-generation product with potential improvements over current pneumococcal vaccines. Antigens in this project are the focus of a Research and Option-for-License Agreement with GlaxoSmithKline.
The BBS1 products are immunotherapeutics for Alzheimer’s disease, both as a monoclonal antibody (MAb) and as an active vaccine that would elicit antibodies of similar specificity as the MAb. The BBS1 product has a novel mechanism of action that makes it distinctive and that could offer certain safety and efficacy advantages over other immunotherapeutic approaches for AD.
